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Abstract
The developments in enteral feeding for
Crohn's disease in the past decade are
critically reviewed. The advent of amino
acid based chemically defined elemental
diets signalled the end of 'total bowel rest'
in the management of these patients.
Subsequently, controlled clinical trials
showed that elemental diets were as effec-
tive as corticosteroids in inducing clinical
remission in patients with acute exacerba-
tions of Crohn's disease. The later use of
peptide based elemental diets, in Crohn's
disease produced somewhat conflicting
results. The initial uncontrolled studies
suggest that polymeric whole protein diets
might also be effective in the management
ofacute exacerbations ofthe disease, cast-
ing in turn doubts concerning the role of
dietary antigens in the pathogenesis of
Crohn's disease. Results of controlled
studies comparing the use of elemental
and polymeric diets as primary therapy in
Crohn's disease have, however, also pro-
duced conflicting results. The results of
one recent controlled trial in which the
use of polymeric diet was compared with
that of corticosteroids does, however,
suggest that these diets may have a
primary therapeutic effect in Crohn's
disease. An analysis of the composition of
some of the enteral diets used in different
trials suggest that the effectiveness of
enteral diets in treating active Crohn's
disease might relate more to their fat than
nitrogen composition. A hypothesis is
proposed that the effectiveness of enteral
nutrition in the primary therapy of acute
exacerbations of Crohn's disease occurs
because the successful diets used contain
insufficient precursors for arachidonate
derived eicosanoid synthesis.
(Gut 1994; supplement 1: S55-S59)
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One of the classic theories concerning the
pathogenesis of inflammatory bowel disease
relates to the possible role of luminal antigens
in triggering acute attack.1-3 Such antigens
have been thought to act by inducing an
anomalous or exaggerated immunological
response causing the release of inflammatory
mediators, which, in turn has been thought
responsible for the clinical and histological
manifestations of the disease.
The possibility that the already damaged
mucosa will be traumatised and therefore
further damaged by food was the main reason
for using 'total bowel rest' in the management
of acute attacks of Crohn's disease.4 'Total
bowel rest' was, however, achieved at the cost
of protein energy malnutrition if standard IV
glucose was the sole source of calories given.
The use of total parenteral nutrition satisfied
the need for 'bowel rest' while permitting the
patient to achieve a satisfactory nutritional
state.5-8 Moreover, the subsequent belief that
intraluminal dietary antigens could play a
major part in the pathophysiology ofinflamma-
tion in Crohn's disease was an additional
reason for prescribing 'total bowel rest' in
patient management.8 10 It has to be empha-
sised that in most series parenteral nutrition
was added to corticosteroid therapy, thus
making the case for total parenteral nutrition
as primary therapy in Crohn's disease confus-
ing. 1 ' There is, however, as far as we are aware
no controlled data to support the use of total
parenteral nutrition as a unique primary
treatment for active Crohn's disease.
In the belief that some food products could
exert an adverse effect on the intestine of
patients with Crohn's disease, the use of
exclusion diets were proposed both as primary
treatment and in the prevention of acute
attacks of the disease.'2 Definitive proof, how-
ever, concerning the relation between the
reintroduction of conventional food ingestion
and relapse of the disease has hitherto not been
provided.
Use of 'elemental' diets in Crohn's
disease
In the past decade much interest has
surrounded the use of predigested chemically
defined elemental diets in the management of
acute exacerbations of Crohn's disease. In the
diets used in the early studies, nitrogen was
provided in the form of free L-amino acids.'3
The rationale for using such diets was based
upon the lower antigenicity of free amino
acids compared with whole protein. In addi-
tion, amino acid, not requiring digestion, was
thought to be well absorbed in the upper seg-
ments of the small bowel. This was considered
to result in some degree of 'bowel rest'.
This idea was reinforced by the fact that the
elemental diets used contained only small
amounts of fat, often in the form of medium
chain triglycerides, which required compara-
tively little luminal lipolysis and micellar
solubilisation before absorption.
A number of controlled clinical trials
comparing the effects of elemental diet and
corticosteroid therapy in the treatment of
acute exacerbations of Crohn's disease were
performed."148 In general, results have shown
that elemental diets are as effective as corti-
costeroids in inducing clinical remission in such
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TABLE I Polymeric diets in Crohn 's disease
Design
PEN v TPN v PPN+oral
PEN
PEN
PEN v EEN
PEN v EEN
PEN v EEN
PEN v EEN
PEN v prednisone
Activity index
CDAI
Harvey
Harvey
CDAI
CDAI
Harvey and Van Hees
CDAI
Van Hees
No Remission (Go) Relapse (%)
51
12
10
30
14
24
30
32
58v71 v60
66
90
36 v 75
71 v29
82 v 78
73 v 66
80 v 88
45 v 58 v 44 (12 months)
66 (15 months)
66 v 100 (12 months)
77 v 66 (12 months)
42 v 67 (12 months)
PEN=polymeric enteral nutrition; EEN=elmental enteral nutrition; TPN=total parenteral nutrition; PPN=peripheral parenteral
nutrition; CDAI=Crohn's disease activity index.
patients; the time taken to achieve the remis-
sion being similar with both treatments. These
findings seemed to support the hypothesis that
both 'bowel rest' and a decrease in antigenic
substances within the intestinal lumen could
diminish the inflammatory response in Crohn's
disease. Later controlled studies have, however,
clearly shown that 'bowel rest' is not a pre-
requisite in the successful treatment of acute
exacerbations of Crohn's disease.'9-21
On the other hand, results about the relapse
rate after remission are controversial. In one
trial, there were no differences in the remission
rate at three months between diet and corticos-
teroids.14 Two later series showed, however,
that the relapse rate after remission induced
by elemental diet was higher than that after
corticosteroids at nine weeks'5 and at 12
months. 18
Use ofpeptide based 'elemental' diets in
Crohn's disease
Based on results of physiological studies
showing better nitrogen absorption from di or
tripeptides than from isonitrogenous free
amino acid mixtures,22 the amino acid source
of some elemental diets has been replaced by
peptide mixtures of varying chain length and
amino acid composition. The osmolality of
amino acid based diets is higher than that of
peptide based diets. Thus, to achieve the same
nitrogen intake, a higher osmotic load would
have to be given using amino acid compared
with peptide or whole protein containing diets.
As diarrhoea in patients with Crohn's disease
receiving enteral feeding might be exacerbated
by the administration of high osmotic loads, it
is perceived by some that the use of the lower
osmolar peptide and whole protein based diets
could result in the supply of more nitrogen in
which case they would be nutritionally more
effective than elemental diets. These consider-
ations may be of importance, as patients with
acute inflammatory bowel disease are hyper-
metabolic23 and often develop protein energy
malnutrition.24
With these arguments in mind, a number of
controlled clinical trials have compared the
efficacy of peptide containing elemental diet
and corticosteroid therapy in the management
of acute exacerbations of Crohn's disease both
in adults25 and children.26 In the largest con-
trolled clinical trial comparing a peptide based
tube fed diet with medical treatment, Lochs
et al found that a peptide based diet was
less effective than a combination of
methylprednisolone and sulphasalazine in the
treatment of active Crohn's disease.25 In
smaller samples of patients, however, peptide
based diets have been shown to be as effective
in inducing remission in Crohn's disease com-
pared with either corticosteroids or amino acid
based diets, with remission rates of higher than
80% being reported.26 28 Note might be made
of the finding in Lochs' trial of 44% of non-
responders to the peptide based diet. This is
surprising as it is a figure considerably higher
than in other trials.
Use ofpolymeric enteral diets in Crohn's
disease
The doubts that have been expressed on the
efficacy of 'bowel rest' as a prerequisite in the
management of acute exacerbations of Crohn's
disease,'9-21 the higher relapse rates in patients
with Crohn's disease treated with amino acid
containing elemental diets than those in corti-
costeroids, and the conflicting results of trials
with peptide based elemental diets have led
other investigators to examine the efficacy of
polymeric, whole protein containing enteral
diets in the management of acute exacerbation
of Crohn's disease.
Several studies have now been published
evaluating the effect of polymeric diets in
Crohn's disease'9 29-34 (Table I). Four are
prospective randomised trials assessing the
efficacy of polymeric diets compared with
'elemental' diets in inducing remission in
Crohn's disease.31-34 The analysis of these
studies is difficult because of (1) The use of
different activity indexes to assess the inflam-
matory activity; (2) Some studies include no
more than 14 cases29 30 32; (3) The diets
studied are not comparable with respect to
their nutritional formulation; (4) The relapse
rates during the follow up have not always been
reported.
It has become traditional to assess inflam-
matory activity in Crohn's disease by means of
clinical and biological parameters and, based
on these, various indexes have been reported;
the Crohn's disease activity index (CDAI)35
and those described by Harvey and Heaton36
and Van Hees et al 37 are most constantly used.
Because the number of variables included in
the first two indexes are subjective - that is,
abdominal pain, degree of well being - their
reproducibility is comparatively low.38 39 In
contrast, all the parameters included 'in the
Van Hees' index can be objectively measured.
The comparative importance of the presence
of diarrhoea varies from one index to another.
This may be of relevance in choosing an index
Author (ref)
Greenberg'9
Coyle29
Bodemar30
Giaffer3
Park32
Raouf33
Rugaud34
Author's series40
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TABLE II Composition of the enteral diets (expressed as per cent of the total calories)
O'MorainI4
Lochs25
Giaffer3
Park32
Royall28
Ito I
Authors49
Nitrogen
(%)
AA (8 2)
PEP (18)
AA (8-2)
POLY (18)
AA(12)
POLY.(13)
AA (8-2)
AA (17-6)
PEP (18-4)
POLY (22)
Carbohydrate Fat
(%/0) (%)
90
70
90
48
78
67
90
89
72
46
1-3 (linoleic
12 (65% linoleic)
1-3 (linoleic)
36 (80% linoleic)
15 (60% MUFA)
19 (60% MUFA)
1-3 (linoleic)
0-6 (linoleic)
5 (linoleic)
32 (50% MUFA)
Result
AA=steroids
PEP<steroids
AA>POLY
POLY>AA
AA=PEP
AA>PEP
POLY=steroids
AA=amino acids; PEP=peptides; POLY=polymeric; MUFA=monounsaturated fatty acids.
for trials assessing the effects of enteral nutri-
tion in Crohn's disease in which an increase in
diarrhoea may either result as a consequence of
worsening of the disease or as a consequence of
side effect of the nutritional treatment. In such
studies, the use of an index as the CDAI that is
loaded towards the daily number of bowel
movements would seem not to be the most
advisable index to use.
In a number of previous studies,19 29 30 33 the
composition of the diets is incompletely
reported as only their elemental or polymeric
character is stated. In some of the studies it is
not clear if the term 'elemental' implies the use
of an amino acid or peptide based nitrogen
source.34 In one trial,3' the nutritional formu-
lation of the diets under investigation is not
comparable. Thus not only did the test diets
have different sources of nitrogen but the lipid
content of the polymeric diet was 15 times
higher than that of the elemental diet. On the
basis of these differences, the conclusion
reached by the authors that polymeric diets are
not as effective in the treatment of Crohn's
disease as elemental diets, may not be justified.
The remaining trials comparing amino
acid or peptide based elemental diets with
C16:0 C18:0
8 I
C18:2n6
| D-6 desaturase l
C18:2n9 C:18:3n6 C18:4n3
elongase C18-20
C20:2n9 C20:3n6 C20:4n3
D-5 desaturase
C20:3n9 C20:4n6 C20:5n3
I I
elongase C20-22 + D-4 desaturase
I I
C22:5n6 C22:6n3
Figure 1: Polyunsaturated fatty acid (PUFA) biosynthesis. n6 and n3 PUFA are
synthesisedfrom essentialfatty acids (linoleic, C18:2n6; and a-linolenic, C18:3n3,
respectively) by alternate desaturation and elongation. Dihomo-T-linolenic (C20:3n6),
arachidonic (C20:4n6), and eicosapentaenoic (C20:5n3) acids are the precursors of
naturally occurring eicosanoids. In severe essentialfatty acid deficiency n9 PUFA may be
producedfrom oleic acid (C18:1). It is noteworthy that each PUFA series produce its
derivatives from its own precursors - that is, they are not interconvertible in vivo.
polymeric diets have shown a positive primary
therapeutic effect of both types of enteral
formulation in Crohn's disease.32-34 To our
knowledge, however, there have been no
studies evaluating the effectiveness of poly-
meric diets in Crohn's disease compared with
corticosteroid therapy. We have recently per-
formed such a study.40 Thirty two patients
with active Crohn's disease were randomised
to receive corticosteroids or a polymeric
enteral diet. The size of this sample allowed us
to detect, with a statistical power of 90°/O and
an ac error of 5%, mean differences in the per
cent reduction of the Van Hees' activity index
between both groups of 20%. The results
showed no differences in the capacity to induce
the remission of the disease (diet 80%, corti-
costeroids 88%). The mean difference in the
per cent reduction of the Van Hees' activity
index between both groups was of 2-5%
(95% confidence intervals -11 188% to 16 8%).
In addition, relapse rate 12 months after
remission was 67% with corticosteroids and
42% with the polymeric diet. The results of
this trial suggest that polymeric enteral nutri-
tion is safe, well tolerated, cheap, and as effec-
tive as corticosteroids in inducing remission in
patients with active Crohn's disease. The trend
towards a lower relapse rate after the induction
of the remission by the diet has to be confirmed
in further studies in which a larger number of
patients are included.
Influence ofthe fat composition of enteral
diets on the outcome in Crohn's disease
We have been interested in assessing the
possible influence that the fat component of
enteral diets has on the outcome of patients
with Crohn's disease. Table II summarises the
composition of some of the enteral diets used
as primary therapy in these patients. Some
interesting points emerge. The use of diets
with a very low fat content (06-1 3 per cent of
total calories) has been associated with a good
outcome.14 28 41 The use ofthose diets contain-
ing high quantities of fat (12-30 per cent of
total calories) was associated overall with a less
favourable outcome. In particular when large
amounts of linoleic acid were present, the out-
come seemed to be poor.25 31 This fatty acid is
the precursor of arachidonic acid, which in
turn is the substrate for the synthesis of the
eicosanoids with the highest proinflammatory
activity (leukotriene B4, thromboxane A2
prostaglandin E2). The outcome of patients
treated with diets containing intermediate or
high amounts of fat but containing large pro-
portions of monounsaturated fatty acids was,
however, more favourable.32 40
These findings suggest the possibility that
clinical remission achieved with elemental
diets might be related to the administration
of insufficient substrate for n-6 derived
eicosanoid synthesis (Fig 1 and 2). In support
of this, there are experimental data available
showing that low fat diets,42 or diets with
low essential fatty acid contents43 have an
immunomodulatory effect in animal studies.
Furthermore, essential fatty acid deficiency is
D-9 desaturase
I
C16:1 C18:1
I
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LTs (4 series) LTs (5 series)
5-Lipooxygenases
KO5~OH KDCYO&COOH - COOH
Dihomo-T-Iinolenic acid Arachidonic acid Eicosapentaenoic acid
Cyclo-oxigenase
PGs y TBXs PGs y TBXs PGs y TBXs
(1 series) (2 series) (3 series)
Figure 2: Eicosanoid (prostaglandin (PG), thromboxane (TBX), and leukotriene(LT))
synthesis from long chain n6 and n3 PUFA.
known to diminish acute inflammation44 and
in other studies to improve experimental colitis
induced in the rat.45 Recent studies in vitro
and in humans emphasise the possible role of
fatty acids and their derivatives in mediating
inflammation.448 In this sense, a changed
plasma pattern of polyunsaturated fatty acids
has been described in inflammatory bowel
disease.49
In conclusion, there are sufficient data avail-
able to suggest that enteral nutrition has a
primary therapeutic role in the management
of acute exacerbations of Crohn's disease.
Further work is needed to explore the possi-
bility that the beneficial effects of enteral
nutrition may not be related, as previously
supposed, to the composition of the nitrogen
source but the composition of the fat compo-
nent of the enteral formulas so far subjected to
clinical trial.
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